Takeda's Investments In Data Science Seek Improved Trial Outcomes, R&D Efficiency

President of R&D Andrew Plump notes that much of the work to rationalize Takeda's pipeline after its Shire acquisition took place years ago when the Japanese pharma streamlined its R&D organization, but investments in data science to improve clinical trial outcomes and R&D efficiency are ongoing.

Futuristic portable device and many pictures.

Takeda Pharmaceutical Co. Ltd. President of Research and Development Andrew Plump's teams will be focused on the integration of Shire PLC's drug candidates into the Japanese pharma's R&D organization over the coming months, and the company's ongoing investments in artificial intelligence, machine learning and digital health may help ensure that the combined pipeline's programs are developed efficiently.

Plump insisted in an interview during the J.P. Morgan Healthcare Conference, conducted a day after Takeda closed its $61bn Shire...